A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Cemiplimab (Primary) ; ISA 101 (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 16 Nov 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 14 Nov 2023 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.